Please login to the form below

pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib , an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,

Latest news

Baxalta and CTI complete filing for Jakafi rival in US

Myelofibrosis candidate pacritinib aiming for accelerated approval. Baxalta and CTI Biopharma have completed their rolling regulatory submission for their myelofibrosis candidate pacritinib in the US, and are aiming for accelerated approval.
Baxter and CTI's Jakafi rival clears phase III trial

Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal. ... year. The trial will also compare pacritinib to best available therapy, but in this case that will include JAK2 inhibitors.
Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Baxter licenses cancer drug from CTI in $172m deal

Specifically, the company's chief executive James Bianco maintains that pacritinib is less prone to causing reductions in blood platelet counts, which can limit treatment. ... he added, noting that additional data on pacritinib will be presented at the
Sanofi pulls development of blood cancer drug

Therapeutics/Baxter's pacritinib.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
Deal Watch table for November 2013

232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Pharma deals during November 2013

Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... The Sanofi decision was taken following reported cases consistent with Wernicke's encephalopathy in patients participating in the clinical trials. Pacritinib, an oral therapy, is

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....